COST UTILITY ANALYSIS OF VEDOLIZUMAB VERSUS CONVENTIONAL THERAPY FOR BIOLOGIC-NAIVE, MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE PATIENTS IN CHINA

被引：0
|
作者：
Sheng, Y. [1 ]
Chen, J. [1 ]
Ma, L. [1 ]
Xie, L. [1 ]
Zhao, W. [2 ]
Han, Y. [3 ]
机构：
[1] Takeda China Inc, Beijing, Peoples R China
[2] WPP Hlth Practice, Shanghai, Peoples R China
[3] Sun Yat Sen Univ, Guangzhou, Peoples R China
来源：
VALUE IN HEALTH | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PGI8
引用
收藏
页码：S533 / S533
页数：1
相关论文
共 50 条
  • [31] Sustained Remission with Adalimumab Therapy in Japanese Patients with Moderately to Severely Active Crohn's Disease
    Hibi, Toshifumi
    Watanabe, Mamoru
    Kumar, Ashish
    Camez, Anne
    Lomax, Kathleen
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2009, 104 : S463 - S463
  • [32] Erratum to: Vedolizumab in moderately to severely active ulcerative colitis or Crohn’s disease: a guide to its use
    Katherine A. Lyseng-Williamson
    Drugs & Therapy Perspectives, 2016, 32 (9) : 406 - 406
  • [33] Subcutaneous vedolizumab in moderately to severely active ulcerative colitis or Crohn’s disease: a profile of its use
    Sheridan M. Hoy
    Drugs & Therapy Perspectives, 2021, 37 : 563 - 572
  • [34] Subcutaneous vedolizumab in moderately to severely active ulcerative colitis or Crohn's disease: a profile of its use
    Hoy, Sheridan M.
    DRUGS & THERAPY PERSPECTIVES, 2021, 37 (12) : 563 - 572
  • [35] EARLY ONSET OF RESPONSE WITH INTRAVENOUS VEDOLIZUMAB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE TREATED IN THE VISIBLE 2 STUDY
    D'Haens, Geer
    Baert, Filip J.
    Danese, Silvio
    Kobayashi, Taku
    Loftus, Edward V.
    Sandborn, William J.
    Dornic, Quentin
    Lindner, Dirk
    Kisfalvi, Krisztina
    Marins, Ed G.
    Vermeire, Sevenne
    GASTROENTEROLOGY, 2021, 160 (06) : S352 - S352
  • [36] Efficacy and safety of vedolizumab subcutaneous formulation in patients with moderately to severely active Crohn's disease: Results of the VISIBLE 2 study
    Vermeire, S.
    Sandborn, W.
    Danese, S.
    Baert, F.
    Kobayashi, T.
    Loftus, E.
    Bhatia, S.
    Kisfalvi, K.
    Rosario, M.
    Zhang, W.
    D'Haens, G.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2020, 35 : 115 - 115
  • [37] COMPARISON OF REAL-WORLD TREATMENT OUTCOMES WITH INFLIXIMAB VERSUS VEDOLIZUMAB IN BIOLOGIC-NAIVE PATIENTS WITH INFLAMMATORY BOWEL DISEASE
    Latremouille-Viau, Dominick
    Burne, Rebecca
    Shi, Sherry
    Adsul, Shashi
    Patel, Haridarshan
    GASTROENTEROLOGY, 2019, 156 (06) : S638 - S639
  • [38] Comparison of Real-World Treatment Outcomes With Vedolizumab Versus Infliximab in Biologic-Naive Patients With Inflammatory Bowel Disease
    Patel, Haridarshan
    Latremouille-Viau, Dominick
    Burne, Rebecca
    Shi, Sherry
    Adsul, Shashi
    CROHNS & COLITIS 360, 2019, 1 (02)
  • [39] Real-world effectiveness and safety of vedolizumab and anti-TNF in biologic-naive Crohn's disease patients: results from the EVOLVE study
    Bressler, B.
    Mantzaris, G.
    Silverberg, M.
    Zezos, P.
    Stein, D.
    Colby, C.
    Lissoos, T.
    Lopez, C.
    Natsios, A.
    Radulescu, G.
    Patel, H.
    Demuth, D.
    Yarur, A.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 : S427 - S428
  • [40] Real-world clinical effectiveness and safety of vedolizumab and ustekinumab in biologic-naive patients with Crohn's disease: Results from the EVOLVE Expansion study
    Ferrante, M.
    Christensen, B.
    Bressler, B.
    Brett, N.
    Bassel, M.
    Kamble, P.
    Adsul, S.
    Gianchetti, L.
    Scharl, M.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 768 - 769
12345